<code id='386B74FF35'></code><style id='386B74FF35'></style>
    • <acronym id='386B74FF35'></acronym>
      <center id='386B74FF35'><center id='386B74FF35'><tfoot id='386B74FF35'></tfoot></center><abbr id='386B74FF35'><dir id='386B74FF35'><tfoot id='386B74FF35'></tfoot><noframes id='386B74FF35'>

    • <optgroup id='386B74FF35'><strike id='386B74FF35'><sup id='386B74FF35'></sup></strike><code id='386B74FF35'></code></optgroup>
        1. <b id='386B74FF35'><label id='386B74FF35'><select id='386B74FF35'><dt id='386B74FF35'><span id='386B74FF35'></span></dt></select></label></b><u id='386B74FF35'></u>
          <i id='386B74FF35'><strike id='386B74FF35'><tt id='386B74FF35'><pre id='386B74FF35'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:9
          Photograph of the logo for BIO, the Biotechnology Innovation Organization, at the BIO International Convention at the Boston Convention and Exhibition Center in 2023
          BIO is proceeding with a restructuring after its new CEO took over. Lane Turner/The Boston Globe

          WASHINGTON — The Biotechnology Innovation Organization on Monday is announcing a significant restructuring accompanied by a shakeup, according to five sources familiar with the planning.

          A few senior leaders are expected to depart as part of the reorganization. Chief Science Officer Cartier Esham, Chief Public Affairs and Marketing Officer Rich Masters, and Chief Policy Officer John Murphy are expected to leave, four sources said. 

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more
          What it’s like to watch children die of measles
          What it’s like to watch children die of measles

          AtoddlerreceivingameaslesvaccinationintheDemocraticRepublicoftheCongo.UNIORKANNAH/AFPviaGettyImagesO

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          The Readout: Amylyx, Alumis, and Lundbeck drug updates

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo